RxDoctor Payments Data

Gregg Etter, MD

Psychiatry · Bristol, RINPI 1962409649

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,169 of the $1,327 with a category attached, or 88.1%. 11 manufacturers reported payments, led by AbbVie at 24.0% of the total. 2025 is the largest year on record at $606, more than ten times the $35 reported in 2019.

$1,327in general payments, 2019–2025

Across 56 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$319
  • Teva Pharmaceuticals USA, Inc.$302
  • E.r. Squibb & Sons, L.L.C.$155
  • Neurocrine Biosciences, Inc.$140
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$139
  • Alkermes, Inc.$136
  • plus $136 from 5 others

What the payments were for

  • Food & beverage$1,16988%
  • Education$15812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,327 in reported general payments places this provider in the 85th percentile of 209 psychiatry providers in Rhode Island.

See all psychiatry providers in Rhode Island

Medicare billing

Part B allowed, 2024
$35,899
Medicare patients
99
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate168$540,058
AristadaAripiprazole Lauroxil29$84,110
Risperidone ErRisperidone Microspheres30$56,692
VivitrolNaltrexone Microspheres24$40,703
Clozapine241$24,798
Perphenazine94$11,427
Bupropion XlBupropion Hcl277$9,943
Aripiprazole129$9,770
Paliperidone ErPaliperidone36$8,353
Haloperidol174$8,286
Divalproex Sodium ErDivalproex Sodium85$8,188
Fluphenazine Hcl42$6,912
Quetiapine Fumarate329$6,581
Duloxetine Hcl168$5,882
Chlorpromazine Hcl31$5,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$20$540,058168 claims
Alkermes, Inc.Aristada, Vivitrol$136$124,81353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 209 psychiatry providers in Rhode Island.

Other psychiatry in Bristol

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →